Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Peginterferon beta-1a
Drug ID BADD_D01697
Description Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.[L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Indications and Usage Peginterferon beta-1a is indicated for the treatment of adult patients with relapsing forms of MS, including relapsing-remitting disease, clinically isolated syndrome, and active progressive secondary disease.[L31428]
Marketing Status approved
ATC Code L03AB13
DrugBank ID DB09122
KEGG ID D10483
MeSH ID C428112
PubChem ID Not Available
TTD Drug ID D0LW4O
NDC Product Code 64406-011; 64406-017; 64406-015; 64406-012; 64406-016
UNII I8309403R0
Synonyms peginterferon beta-1a | polyethylene glycol-interferon-beta-1a | PEG IFN-beta-1a | polyethylene glycol-interferon beta-1a | Plegridy
Chemical Information
Molecular Formula Not Available
CAS Registry Number 1211327-92-2
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vomiting07.01.07.003--
Neutralising antibodies13.06.03.010---
Antibody test13.06.03.009---
Autoimmune disorder10.04.04.003--
Liver injury09.01.07.022; 12.01.17.012---
The 2th Page    First    Pre   2    Total 2 Pages